Psilocybin

Psyence Biomedical's Phase IIb trial of nature-derived psilocybin with psychotherapy for Adjustment Disorder in Palliative Care progresses with two Australian sites activated and patient screening underway. First patients expected in January, with therapist training ongoing. Additional sites under evaluation, and ACTioN SMO aiding recruitment through social media and direct communications.

Psyence Biomed's Phase IIb trial for nature-derived psilocybin with psychotherapy in Adjustment Disorder following cancer diagnosis progresses, with two Australian sites activated and patient screening underway. First patients expected to be randomized in January, with ACTioN SMO aiding recruitment through social media and direct communications. Topline results anticipated in H2 2025.

DEA increases 2025 DMT production quota to 20,000 grams to support FDA-approved drug development, citing research needs and public comments. Several companies are exploring DMT for treating mental health conditions and brain injuries.

A University of Washington Medicine study found psilocybin-assisted psychotherapy significantly reduces burnout and depression in healthcare workers, especially those on the COVID-19 front lines. Participants reported lasting benefits, with the treatment enabling them to confront and process their trauma, leading to improved mental health and job performance.

Oregon's psychedelic program, focusing on psilocybin treatment, saw its first full year in 2024 with hundreds of trained specialists and thousands of treatments completed with few adverse effects. The program aims to refine and study its impacts in 2025, addressing issues of cost, availability, and insurance coverage. Preliminary research results are expected in early 2025, potentially influencing policy and insurance coverage.